Serum tocilizumab trough concentration can be used to monitor systemic IL-6 receptor blockade in patients with rheumatoid arthritis: a prospective observational cohort study

Scandinavian Journal of Rheumatology

Volumn 46, Issue 2, 2017, Pages 87-94

  Kneepkens, E L ^a   van den Oever, I A M ^a   Plasencia, C H ^b   Pascual Salcedo, D ^b   de Vries, A ^c   Hart, M ^d   Nurmohamed, M T ^a,e   Balsa, A ^b   Rispens, T ^d   Wolbink, G ^a,d  

^a Amsterdam Rheumatology and Immunology Center   (Netherlands)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c Sanquin Diagnostiek   (Netherlands)

^d SANQUIN RESEARCH   (Netherlands)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; DRUG ANTIBODY; INTERLEUKIN 6; TOCILIZUMAB; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; COHORT ANALYSIS; DAS28; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; UNSPECIFIED SIDE EFFECT; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; BLOOD; DOSE RESPONSE; DRUG MONITORING; METABOLISM;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, INTERLEUKIN-6;

EID: 84978951824     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.1080/03009742.2016.1183039     Document Type: Article

References (45)

1. Swaak AJ, van Rooyen A, Nieuwenhuis E, Aarden L., Interleukin-6 (IL-6) in synovial fluid and serum of patients with rheumatic diseases. Scand J Rheumatol 1988;17:469–74.
2. Usón J, Balsa A, Pascual-Salcedo D, Cabezas JA, Gonzalez-Tarrio JM, Martín-Mola E, et al. Soluble interleukin 6 (IL-6) receptor and IL-6 levels in serum and synovial fluid of patients with different arthropathies. J Rheumatol 1997;24:2069–75.
3. Kotake S, Sato K, Kim KJ, Takahashi N, Udagawa N, Nakamura I, et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 1996;11:88–95.
4. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007;7:429–42.
5. Lipsky PE. Interleukin-6 and rheumatic diseases. Arthritis Res Ther 2006;8(Suppl 2):S4.
6. Castell JV, Geiger T, Gross V, Andus T, Walter E, Hirano T, et al. Plasma clearance, organ distribution and target cells of interleukin-6/hepatocyte-stimulating factor in the rat. Eur J Biochem 1988;177:357–61.
7. Kato A, Watanabe T, Yamazaki M, Deki T, Suzuki M. IL-6R distribution in normal human and cynomolgus monkey tissues. Regul Toxicol Pharmacol 2009;53:46–51.
8. Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor:importance for the pro-inflammatory activities of IL-6. Int J Biol Sci 2012;8:1237–47.
9. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study):a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987–97.
10. Maini RN, Taylor PC, Szechinski J, Pavelka K, Bröll J, Balint G, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006;54:2817–29. Erratum in Arthritis Rheum 2008;3:887.
11. Ogata A, Tanimura K, Sugimoto T, Inoue H, Urata Y, Matsubara T, et al. Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2014;66:344–54.
12. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008;112:3959–64.
13. Levi M, Grange S, Frey N. Exposure-response relationship of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in a large population of patients with rheumatoid arthritis. J Clin Pharmacol 2013;53:151–9.
14. Frey N, Grange S, Woodworth T. Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis. J Clin Pharmacol 2010;50:754–66.
15. Arora A, Mahajan A, Spurden D, Boyd H, Porter D. Long-term drug survival of TNF inhibitor therapy in RA patients:a systematic review of European National Drug Registers. Int J Rheumatol 2013;2013:764518.
16. Maneiro JR, Salgado E, Gomez-Reino JJ. Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated inflammatory conditions:systematic review and meta-analysis. JAMA Intern Med 2013;173:1416–28.
17. Nishina N, Kikuchi J, Hashizume M, Yoshimoto K, Kameda H, Takeuchi T. Baseline levels of soluble interleukin-6 receptor predict clinical remission in patients with rheumatoid arthritis treated with tocilizumab:implications for molecular targeted therapy. Ann Rheum Dis 2014;73:945–7.
18. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
19. Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44–8.
20. Food and Drug Administration. 2013 (http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125276s064lbl.pdf). Accessed 22 June 2016.
21. Rispens T, Leeuwen Av, Vennegoor A, Killestein J, Aalberse RC, Wolbink GJ, et al. Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody. Anal Biochem 2011;411:271–6.
22. Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:711–15.
23. Rispens T, de Vrieze H, de Groot E, Wouters D, Stapel S, Wolbink GJ, et al. Antibodies to constant domains of therapeutic monoclonal antibodies:anti-hinge antibodies in immunogenicity testing. J Immunol Methods 2012;375:93–9.
24. Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011;305:1460–8.
25. Hart MH, de Vrieze H, Wouters D, Wolbink GJ, Killestein J, de Groot ER, et al. Differential effect of drug interference in immunogenicity assays. J Immunol Methods 2011;372:196–203.
26. Wolbink GJ, Aarden LA, Dijkmans BA. Dealing with immunogenicity of biologicals:assessment and clinical relevance. Curr Opin Rheumatol 2009;21:211–15.
27. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552–63.
28. Chaigne B, Watier H., Monoclonal antibodies in excess:A simple way to avoid immunogenicity in patients? J Allergy Clin Immunol 2015;136:814–16.
29. van Schouwenburg PA, Bartelds GM, Hart MH, Aarden L, Wolbink GJ, Wouters D. A novel method for the detection of antibodies to adalimumab in the presence of drug reveals “hidden” immunogenicity in rheumatoid arthritis patients. J Immunol Methods 2010;362:82–8.
30. Bloem K, van Leeuwen A, Verbeek G, Nurmohamed MT, Wolbink GJ, van der Kleij D, et al. Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients. J Immunol Methods 2015;418:29–38.
31. Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M, et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol 2005;5:1731–40.
32. Wang J, Platt A, Upmanyu R, Germer S, Lei G, Rabe C, et al. IL-6 pathway-driven investigation of response to IL-6 receptor inhibition in rheumatoid arthritis. BMJ Open 2013;8:e003199.
33. Enevold C, Baslund B, Linde L, Josephsen NL, Tarp U, Lindegaard H, et al. Interleukin-6-receptor polymorphisms rs12083537, rs2228145, and rs4329505 as predictors of response to tocilizumab in rheumatoid arthritis. Pharmacogenet Genomics 2014;24:401–5.
34. Aletaha D, Nell VPK, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis:validation of a clinical activity score. Arthritis Res Ther 2005;7:R796–806.
35. Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003;42:244–57.
36. Ohta S, Tsuru T, Terao K, Mogi S, Suzaki M, Shono E, et al. Mechanism-based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study). J Clin Pharmacol 2014;54:109–19.
37. Wang J, Devenport J, Low J, Yu D, Hitraya E. Relationship between baseline/early changes in c-reactive protein and interleukin-6 and clinical response to tocilizumab for rheumatoid arthritis. Arthritis Care Res (Hoboken) 2016;68:882–5.
38. Yarur AJ, Jain A, Sussman DA, Barkin JS, Quintero MA, Princen F, et al. The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease:the ATLAS study. Gut 2016;65:249–55.
39. Colombel JF, Sandborn WJ, Allez M, Dupas JL, Dewit O, D’Haens G, et al. Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn’s disease. Clin Gastroenterol Hepatol 2014;12:423–31.e1.
40. Pouw MF, Krieckaert CL, Nurmohamed MT, van der Kleij D, Aarden L, Rispens T, et al. Key findings towards optimising adalimumab treatment:the concentration-effect curve. Ann Rheum Dis 2015;74:513–18.
41. Menting SP, Coussens E, Pouw MF, van den Reek JMPA, Temmerman L, Boonen H, et al. Developing a therapeutic range of adalimumab serum concentrations in management of psoriasis:a step toward personalized treatment. JAMA Dermatol 2015;151:616–22.
42. Kaneko A, Kida D, Saito K, Tsukamoto M, Sato T. Clinical results for tocilizumab over one year in the clinical setting as assessed by CDAI (clinical disease activity index):CRP at week 12 and MMP-3 at week 24 are predictive factors for CDAI. Rheumatol Int 2012;32:3631–7.
43. Pers YM, Fortunet C, Constant E, Lambert J, Godfrin-Valnet M, De Jong A, et al. Predictors of response and remission in a large cohort of rheumatoid arthritis patients treated with tocilizumab in clinical practice. Rheumatology (Oxford) 2014;53:76–84.
44. Inciarte-Mundo J, Ruiz-Esquide V, Hernández MV, Cañete JD, Cabrera-Villalba SR, Ramirez J, et al. Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactants. Rheumatology (Oxford) 2015;54:2239–43.
45. Burmester GR, Rigby W, van Vollenhoven RF, Kay J, Rubbert-Roth A, Kelman A, et al. Tocilizumab in combination therapy and monotherapy versus methotrexate in methotrexate-naïve patients with early rheumatoid arthritis:clinical and radiographic outcomes from a randomized placebo-controlled trial. Arthritis Rheumatol 2013;65:(Suppl S1);182–3.